is semaglutide for type 2 diabetes Oral and Cardiovascular Outcomes in Semaglutide ⏺Type 2 diabetes mellitus

Month 12: approaching maximum effect The STEP 1 trial showed that average weight loss approached its nadir around week 60, roughly month 15

Step 5: Ongoing Monitoring and Refills Compounding pharmacies do not manage lab monitoring

10 , e12411 (2020)

The FDA has approved Wegovy (semaglutide) and Zepbound (tirzepatide) specifically for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia

Having the numbers in front of you during dose preparation eliminates calculation errors

FAQs Q1: Is it safe to switch from tirzepatide to semaglutide